The latest spat over the potential approval of aducanumab, an amyloid-β-targeting drug for Alzheimer’s disease, highlights continuing controversy over the amyloid-β hypothesis.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Massie, T. Statistical review aducanumab in Alzheimer’s. FDA https://collaboration.fda.gov/pradgevcxis7 (2020).
Mintun, M. A. et al. New Engl. J. Med. https://doi.org/10.1056/NEJMoa2100708 (2021).
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Zipkin, M. Alzheimer’s amyloid-β drug hangs in the balance. Nat Aging 1, 324–326 (2021). https://doi.org/10.1038/s43587-021-00059-x